G. Fiorentini

746 total citations
37 papers, 515 citations indexed

About

G. Fiorentini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, G. Fiorentini has authored 37 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in G. Fiorentini's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Sarcoma Diagnosis and Treatment (6 papers). G. Fiorentini is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Sarcoma Diagnosis and Treatment (6 papers). G. Fiorentini collaborates with scholars based in Italy, United Kingdom and Greece. G. Fiorentini's co-authors include Maurizio Cantore, Paolo Bernardeschi, Ugo De Giorgi, Andrea Mambrini, M. Marangolo, Carla Rabbi, Claudio Dazzi, Andrea Manni, Calogero Iacono and Cristina Oliani and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

G. Fiorentini

36 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Fiorentini Italy 15 228 212 134 68 62 37 515
Daniel Oruzio Germany 14 426 1.9× 149 0.7× 91 0.7× 72 1.1× 89 1.4× 30 658
Joëlle Marchal France 12 150 0.7× 389 1.8× 108 0.8× 46 0.7× 138 2.2× 16 707
Andréa Cavalcanti France 11 314 1.4× 174 0.8× 162 1.2× 40 0.6× 117 1.9× 30 631
Judith E. Woll United States 12 171 0.8× 93 0.4× 116 0.9× 54 0.8× 73 1.2× 26 503
John Champion United States 14 171 0.8× 221 1.0× 88 0.7× 27 0.4× 83 1.3× 16 464
Eun Deok Chang South Korea 14 194 0.9× 139 0.7× 170 1.3× 88 1.3× 154 2.5× 30 616
Ken Kikuchi Japan 16 420 1.8× 176 0.8× 350 2.6× 50 0.7× 121 2.0× 35 971
Funda Obuz Türkiye 18 373 1.6× 165 0.8× 423 3.2× 33 0.5× 92 1.5× 72 908
Anna Cariello Italy 12 196 0.9× 156 0.7× 55 0.4× 55 0.8× 69 1.1× 22 411
G Gariépy Canada 11 378 1.7× 204 1.0× 230 1.7× 49 0.7× 53 0.9× 33 745

Countries citing papers authored by G. Fiorentini

Since Specialization
Citations

This map shows the geographic impact of G. Fiorentini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Fiorentini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Fiorentini more than expected).

Fields of papers citing papers by G. Fiorentini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Fiorentini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Fiorentini. The network helps show where G. Fiorentini may publish in the future.

Co-authorship network of co-authors of G. Fiorentini

This figure shows the co-authorship network connecting the top 25 collaborators of G. Fiorentini. A scholar is included among the top collaborators of G. Fiorentini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Fiorentini. G. Fiorentini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pucciarelli, Stefania, Giulia Bonacucina, Valeria Polzonetti, et al.. (2014). Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions. Current Pharmaceutical Biotechnology. 15(2). 113–119. 22 indexed citations
2.
Rossi, Giuseppe, Andreas F. Mavrogenis, Eugenio Rimondi, et al.. (2011). Selective arterial embolisation for bone tumours: experience of 454 cases. La radiologia medica. 116(5). 793–808. 43 indexed citations
3.
Bernardeschi, Paolo, et al.. (2011). Targeted-Therapy in Advanced Renal Cell Carcinoma. Current Medicinal Chemistry. 18(11). 1651–1657. 33 indexed citations
4.
Mambrini, Andrea, Antonello Di Paolo, Paola Pacetti, et al.. (2008). Pharmacokinetics of irinotecan: Comparison of intravenous and intra-arterial administration in patients with liver metastases. Journal of Clinical Oncology. 26(15_suppl). 14608–14608. 2 indexed citations
5.
Guadagni, Stefano, Marco Clementi, Marco Valenti, et al.. (2006). Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: A phase II evaluation/trial. European Journal of Surgical Oncology. 33(1). 72–78. 15 indexed citations
6.
Ambrosini, Valentina, Cristina Nanni, Domenico Rubello, et al.. (2006). 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. La radiologia medica. 111(8). 1146–1155. 38 indexed citations
7.
Giorgi, Ugo De, Alberto Pupi, G. Fiorentini, Giovanni Rosti, & M. Marangolo. (2005). FDG-PET in the management of germ cell tumor. Annals of Oncology. 16. iv90–iv94. 14 indexed citations
8.
Romi, Roberto, Giorgio Pontuale, Maria Grazia Ciufolini, et al.. (2004). Potential vectors of West Nile Virus following an equine disease outbreak in Italy. Medical and Veterinary Entomology. 18(1). 14–19. 45 indexed citations
9.
Cantore, Maurizio, G. Fiorentini, Gabriele Luppi, et al.. (2004). Ceravolo. Journal of Chemotherapy. 16(6). 589–594. 21 indexed citations
10.
Cantore, Maurizio, Carla Rabbi, G. Fiorentini, et al.. (2004). Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer. Oncology. 67(2). 93–97. 65 indexed citations
11.
Soriani, Marie‐Hélène, et al.. (2004). Radiofrequency Ablation of Liver Malignancies: MRI for Evaluation of Response. Journal of Chemotherapy. 16(sup5). 79–81. 10 indexed citations
12.
Piga, A., Rolando Nortilli, Gian Luigi Cetto, et al.. (2004). Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. British Journal of Cancer. 90(10). 1898–1904. 19 indexed citations
13.
Vaira, Marco, et al.. (2003). Treatment of pseudomyxoma peritonei with two times--cytoreduction and hypertermic antiblastic peritoneal perfusion (HAPP).. PubMed. 22(4 Suppl). 25–8. 2 indexed citations
14.
Fiorentini, G., Petros Giovanis, Marina Leoni, et al.. (2001). Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.. PubMed. 48(38). 313–6. 3 indexed citations
15.
Cantore, Maurizio, G. Fiorentini, Claudio Bassi, et al.. (1997). Intra-Arterial Chemotherapy for Stage-lll/IV Pancreatic Cancer. Digestive Surgery. 14(2). 113–118. 9 indexed citations
16.
Fiorentini, G., D Poddie, Maurizio Cantore, et al.. (1994). Hepatic arterial infusion (HAI) of high dose chemotherapy plus caval chemofiltration vs HAI of prolonged low doses in patients with liver matastases from colorectal carcinoma: Result of a prospective randomized trial.. 7. 165–168. 3 indexed citations
17.
Donini, Annibale, et al.. (1994). [Treatment with immunomodulating drugs of patients with operated cancer. Long-term results].. PubMed. 49(11). 1101–5. 1 indexed citations
18.
Fiorentini, G., Claudio Dazzi, Alfredo Guglielmi, et al.. (1992). Intra-arterial hepatic chemotherapy combined with chemofiltration in liver malignancies: results of the Italian experience. 5. 159–162. 1 indexed citations
19.
Marangolo, M., A. Tienghi, G. Fiorentini, et al.. (1992). Treatment of pelvic osteosarcoma. Annals of Oncology. 3. S19–S21. 13 indexed citations
20.
Fiorentini, G., et al.. (1985). Early gastric cancer: evaluation of diagnostic, clinicopathologic and therapeutic aspects in 60 cases.. PubMed. 69(4). 325–30. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026